The effect of Mounjaro on endometrial treatment
Medicines Mouniaro (tirzepatide) may have a significant indirect effect on health endometrial health, especially in women with obesity, PCOS or prolonged irregular menstrual cycles. In these conditions, the endometrium is often exposed to prolonged estrogen action without adequate progesterone balance, increasing the risk of endometrial hyperplasia.
As weight loss and insulin sensitivity improve, it can be restored regular ovulation and thus normal progesterone function. This allows for a more physiological renewal of the endometrium and reduces the risk of excessive thickening of the lining of the uterus. As a consequence, it may also improve regularity of menstrual bleeding.
In the long term, improved hormonal and metabolic balance can reduce the risk of the progression of hyperplasia to endometrial cancerwhich is more common in women with obesity and PCOS. Mounjar treatment can therefore form an important part of preventive treatment aimed at protecting endometrial health.